NATHBIOGEN Nath Bio-Genes (India) Q4 FY25 results (Jan–Mar 2025) and concall
Nath Bio-Genes reported a resilient FY25 with total revenue of INR362.30 crores and PAT of INR41.6 crores, up 13.3% YoY. The company's diversification strategy bore fruit, with the non-cotton, non-paddy (NCP) segment growing 38% and contributing 48% to revenue. While EBITDA growth was modest at 4% due to market support, Nath Bio-Genes strengthened its financial position with improved working capital and a credit rating upgrade, setting the stage for future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 32 | 37 | 49 |
| EBITDA | 7 | 8 | 3 |
| Net profit | 3 | 3 | 5 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
